These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
996 related articles for article (PubMed ID: 26616112)
1. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma. Shwetha SD; Shastry AH; Arivazhagan A; Santosh V Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112 [TBL] [Abstract][Full Text] [Related]
2. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753 [TBL] [Abstract][Full Text] [Related]
3. Differential expression of a novel voltage gated potassium channel--Kv 1.5 in astrocytomas and its impact on prognosis in glioblastoma. Arvind S; Arivazhagan A; Santosh V; Chandramouli BA Br J Neurosurg; 2012 Feb; 26(1):16-20. PubMed ID: 21707241 [TBL] [Abstract][Full Text] [Related]
4. Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas. Shastry AH; Thota B; Srividya MR; Arivazhagan A; Santosh V Pathol Oncol Res; 2016 Apr; 22(2):287-92. PubMed ID: 26253838 [TBL] [Abstract][Full Text] [Related]
5. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363 [TBL] [Abstract][Full Text] [Related]
7. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas. Suren D; Isiksacan Ozen O J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030 [TBL] [Abstract][Full Text] [Related]
8. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078 [TBL] [Abstract][Full Text] [Related]
9. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127 [TBL] [Abstract][Full Text] [Related]
10. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma. Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. Chaurasia A; Park SH; Seo JW; Park CK J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330 [TBL] [Abstract][Full Text] [Related]
12. The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications. Ria F; Landriscina M; Remiddi F; Rosselli R; Iacoangeli M; Scerrati M; Pani G; Borrello S; Galeotti T Br J Cancer; 2001 Feb; 84(4):529-34. PubMed ID: 11207049 [TBL] [Abstract][Full Text] [Related]
13. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of vascular adhesion protein-1 is associated with poor prognosis of astrocytomas. Kostoro J; Chang SJ; Clark Lai YC; Wu CC; Chai CY; Kwan AL APMIS; 2016 Jun; 124(6):462-8. PubMed ID: 26935340 [TBL] [Abstract][Full Text] [Related]
16. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311 [TBL] [Abstract][Full Text] [Related]
18. Role of gemistocytes in astrocytoma progression. Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of chemokine receptor CXCR3 and its ligand CXCL10 in low-grade astrocytomas and glioblastoma multiforme: A tissue microarray-based comparison. Sharma I; Siraj F; Sharma KC; Singh A J Cancer Res Ther; 2016; 12(2):793-7. PubMed ID: 27461653 [TBL] [Abstract][Full Text] [Related]
20. Expression and mutation analysis of the p53 gene in astrocytoma. Hwang SL; Hong YR; Sy WD; Chai CY; Lin HJ; Howng SL J Formos Med Assoc; 1999 Jan; 98(1):31-8. PubMed ID: 10063271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]